Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
Sonire Therapeutics has initiated its first U.S. clinical trial, SUNRISE-II, to evaluate its ultrasound-guided High-Intensity Focused Ultrasound (HIFU) therapy system for pancreatic cancer. The trial aims to assess the safety and feasibility of this minimally invasive, anesthesia-free treatment approach.
SUNRISE-II feasibility trial marks the company’s entry into U.S. clinical development, advancing minimally invasive, anesthesia-free treatment approach PALO ALTO, Calif., May 1, 2026 /PRNewswire/ — Sonire Therapeutics, a U.S.-based clinical-stage medical device company, today announced…